Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06821100 · ClinicalTrials.gov registry record · Phase 1
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
A Phase 1 study of COVID-19 Vaccine and Vaccine Response, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06821100: Recruiting Phase 1 study of COVID-19 Vaccine and Vaccine Response, sponsored by The Methodist Hospital Research Institute.
NCT06821100 is a Phase 1 study of COVID-19 Vaccine and Vaccine Response that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 75 participants, below the 5,881-participant average among 6 other COVID-19 Vaccine trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06821100, a Phase 1 study of COVID-19 Vaccine and Vaccine Response, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections. This research study will test the safety and possible harms of Ta1 when it is given to people at different dose levels before COVID-19 vaccination.
Primary Outcome
The primary objective is to evaluate the safety and tolerability of different treatment regimens of Ta1 before vaccination with a SARS-CoV-2 mRNA vaccine. This will be measured by: \- The incidence and severity of adverse events (AEs) following treatment
Conditions Studied
Interventions
- DRUG Thymalfasin (Thymosin alpha 1, Ta1)
Study Locations (1)
Texas
- Houston Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
What NCT06821100 shows while recruiting
NCT06821100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 5,881-participant average among 6 other COVID-19 Vaccine trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with COVID-19 Vaccine appearing as the primary indexed condition, and to 1 intervention - of which Thymalfasin (Thymosin alpha 1, Ta1) is the first listed.
NCT06821100 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06821100 about?
NCT06821100 is a clinical study titled "Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine". The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections. This research study will ...
What is the current status of trial NCT06821100?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2024-12-02. Estimated completion is 2026-12-01.
What conditions does trial NCT06821100 study?
This clinical trial studies the following conditions: COVID-19 Vaccine, Vaccine Response, Immune Response to Covid 19 Vaccination.
What interventions are being tested in trial NCT06821100?
The interventions under investigation include: Thymalfasin (Thymosin alpha 1, Ta1) (DRUG).
Who is sponsoring clinical trial NCT06821100?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06821100 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19 Vaccine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pancoronavirus Vaccine Study in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health
RECRUITING
-
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
RECRUITING
-
COVID-19 Vaccines Safety Tracking (CoVaST)
RECRUITING
-
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
ACTIVE NOT RECRUITING · NA
-
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI